Skip to main content

Dr. Andrew M. Brunner, M.D.

Hematology & Oncology (Hematology & Oncology Physician)

  • Medicare participating

At a glance

Years since graduation
16
In the NPI registry since
2010
Medicare patients seen, 2024
153

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is

Education and training

  • 2010Medical school: Warren Alpert Medical School of Brown University
  • 2010Registered with an NPI (national billing number; not a license date)

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Hematology & Oncology Physician primary
    MA license 252646
  • Internal Medicine Physician
    MA license L-243818

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Hematology & Oncology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
153
Services billed
873
Patients’ average age
77
Most frequent Medicare services, 2023
ServiceTimesPatients
Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes27456
Established patient office or other outpatient visit, 30-39 minutes23063
Established patient office or other outpatient visit, 40-54 minutes14650
Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes2322
Hospital discharge day management, more than 30 minutes1919

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Most prescribed drugs, Medicare Part D 2024
DrugPrescriptions
Acyclovir
Other prescribers in Boston, MA
35
Omeprazole
Other prescribers in Boston, MA
17
Allopurinol
Other prescribers in Boston, MA
11
Inqovi (decitabine/cedazuridine)11
Deferasirox11

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 9 companies reported 25 payments worth $14,739 in total to this clinician.

By type
Consulting Fee$11,484
Compensation for services other than consulting (speaking, faculty)$2,200
Food and Beverage$634
Travel and Lodging$378
Education$43.25

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Sep 18, 2025Syndax Pharmaceuticals, Inc.
Sep 18, 2025
Consulting Fee
REVUFORJ · HEMATOLOGY-ONCOLOGY
$6,081
Jul 1, 2025E.r. Squibb & Sons, L.l.c.
Jul 1, 2025
Consulting Fee$2,865
Jul 1, 2025Geron Corporation
Jul 1, 2025
Compensation for services other than consulting (speaking, faculty)
IMETELSTAT · HEMATOLOGY
$2,200
Jun 9, 2025AbbVie Inc.
Jun 9, 2025
Consulting Fee
VENCLEXTA · ONCOLOGY
$1,450
Jul 10, 2025GlaxoSmithKline, LLC.
Jul 10, 2025
Consulting Fee$725
Jan 24, 2025AbbVie Inc.
Jan 24, 2025
Consulting Fee
VENCLEXTA · ONCOLOGY
$363
Dec 5, 2025Celgene Corporation
Dec 5, 2025
Travel and Lodging
travel to Orlando, FL
$197
Sep 18, 2025Syndax Pharmaceuticals, Inc.
Sep 18, 2025
Travel and Lodging
REVUFORJ · HEMATOLOGY-ONCOLOGY · travel to CHICAGO, IL
$150
Nov 25, 2025AstraZeneca Pharmaceuticals LP
Nov 25, 2025
Education
ENHERTU · Oncology · in-kind
Company’s descriptionJournal Article
$43.25
Sep 18, 2025Syndax Pharmaceuticals, Inc.
Sep 18, 2025
Travel and Lodging
REVUFORJ · HEMATOLOGY-ONCOLOGY · travel to CHICAGO, IL
$30.60

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Massachusetts →

Industry-funded research

Named as a principal investigator on 8 industry-funded studies in 2025, from 6 companies. The companies reported $542,537 in research payments for these studies, mostly to the institutions running them.

  • A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplasti…
    Taiho Oncology, Inc.
  • A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
    Sumitomo Pharma America, Inc. · Recruiting · NCT04988555
  • TIM3 Inhibition with MBG453 for Patients with Lower Risk MDS
    Novartis Pharmaceuticals Corporation
  • Phase 2 Study of Mitoxantrone, Etoposide, and Cytarabine (MEC) plus Lenalidomide for the treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia
    Celgene Corporation
  • Phase II Trial of AZD6738 Monotherapy for Myelodysplastic Syndrome Unresponsive or Intolerant to First Line Therapy
    AstraZeneca Pharmaceuticals LP
  • A Phase 2a/2b, Open-label, Proof of Concept (Phase 2a) and Open-label (Phase 2b), Multicenter, Efficacy, and Safety Study of AG-946 in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes
    Agios Pharmaceuticals, Inc.
  • A Phase Ib, multicenter, open-label platform study of select drug combinations in adult patients with lower risk (very low, low, or intermediate risk) myelodysplastic syndrome
    Novartis Pharmaceuticals Corporation
  • Phase II Trial of Immunotherapy with MEDI4736 With Continuous or Intermittent MEK Inhibitor Selumetinib in KRAS Mutant NSCLC
    AstraZeneca Pharmaceuticals LP

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Hematology & Oncology clinicians in Boston

Sources

NPI registry (CMS NPPES, November 2026; record last updated April 6, 2016), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1699095166. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.